TY - JOUR
T1 - Advances in the development of aptamer drug conjugates for targeted drug delivery
AU - Chen, Ke
AU - Liu, Bo
AU - Yu, Bo
AU - Zhong, Wen
AU - Lu, Yi
AU - Zhang, Jiani
AU - Liao, Jie
AU - Liu, Jun
AU - Pu, Ying
AU - Qiu, Liping
AU - Zhang, Liqin
AU - Liu, Huixia
AU - Tan, Weihong
N1 - Funding Information:
This research was supported by NSFC grants (NSFC 21502050, NSFC 81370983, NSFC 8140086410, NSFC 81500692, NSFC 21521063, and NSFC 21327009), the Foundation of National Key Scientific Instrument and Equipment Development Projects (2011YQ0301241403), the Hunan Province Natural Science Key Fund Project (2014SK2003), the Foundation of China Hunan Provincial Science & Technology Department (2012FJ4371, S2014S2032, 2010SK2003), the Science & Research Foundation of Hunan Health Department (B2010-007, 132013-010, 132011-014), Fundamental Research Funds for the Central Universities of Central South University (2013 zzts083), and the Youth Scientific Fund of Xiangya Hospital (2015Q03). This work is also supported by the National Institutes of Health (GM079359, GM111386, and CA133086).
Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - A key goal of modern medicine is target-specific therapeutic intervention. However, most drugs lack selectivity, resulting in ‘off-target’ side effects. To address the requirements of ‘targeted therapy,’ aptamers, which are artificial oligonucleotides, have been used as novel targeting ligands to construct aptamer drug conjugates (ApDC) that can specifically bind to a broad spectrum of targets, including diseased cells. Accordingly, the application of aptamers in targeted drug delivery has attracted broad interest due to their impressive selectivity and affinity, low immunogenicity, easy synthesis with high reproducibility, facile modification, and relatively rapid tissue penetration with no toxicity. Functionally, aptamers themselves can be used as macromolecular drugs, and they are also commonly used in biomarker discovery and targeted drug delivery. In this review, we will highlight the most recent advances in the development of aptamers and aptamer conjugates, and discuss their potential in targeted therapy. WIREs Nanomed Nanobiotechnol 2017, 9:e1438. doi: 10.1002/wnan.1438. For further resources related to this article, please visit the WIREs website.
AB - A key goal of modern medicine is target-specific therapeutic intervention. However, most drugs lack selectivity, resulting in ‘off-target’ side effects. To address the requirements of ‘targeted therapy,’ aptamers, which are artificial oligonucleotides, have been used as novel targeting ligands to construct aptamer drug conjugates (ApDC) that can specifically bind to a broad spectrum of targets, including diseased cells. Accordingly, the application of aptamers in targeted drug delivery has attracted broad interest due to their impressive selectivity and affinity, low immunogenicity, easy synthesis with high reproducibility, facile modification, and relatively rapid tissue penetration with no toxicity. Functionally, aptamers themselves can be used as macromolecular drugs, and they are also commonly used in biomarker discovery and targeted drug delivery. In this review, we will highlight the most recent advances in the development of aptamers and aptamer conjugates, and discuss their potential in targeted therapy. WIREs Nanomed Nanobiotechnol 2017, 9:e1438. doi: 10.1002/wnan.1438. For further resources related to this article, please visit the WIREs website.
UR - http://www.scopus.com/inward/record.url?scp=84996956308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996956308&partnerID=8YFLogxK
U2 - 10.1002/wnan.1438
DO - 10.1002/wnan.1438
M3 - Review article
C2 - 27800663
AN - SCOPUS:84996956308
SN - 1939-0041
VL - 9
JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
IS - 3
M1 - e1438
ER -